MedTrace Logo

Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease

NCT00002652 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-02-04

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of suramin in treating patients who have refractory or relapsed multiple myeloma or Castleman's disease.

Conditions

  • Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG

suramin

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Nikhil C. Munshi, MD · University of Arkansas

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1995-05-31
Completion
2004-02-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002652 on ClinicalTrials.gov